SEC Form 4 
FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 	  
OMB APPROVAL
OMB Number:	3235-0287	
Estimated average burden	
hours per response:	0.5	

	
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			
1. Name and Address of Reporting Person*
Ulys, LLC	

(Last)	(First)	(Middle)	
750 LEXINGTON AVENUE	
30TH FLOOR	

(Street) 
NEW YORK	NY	10022	

(City)	(State)	(Zip)	
	2. Issuer Name and Ticker or Trading Symbol 
LEXICON PHARMACEUTICALS, INC./DE [ LXRX ] 	5. Relationship of Reporting Person(s) to Issuer 
(Check all applicable) 
	Director	X	10% Owner	
	Officer (give title below)		Other (specify below)	

	3. Date of Earliest Transaction (Month/Day/Year)
10/14/2009 		
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) 
	Form filed by One Reporting Person	
X	Form filed by More than One Reporting Person	
	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned	
1. Title of Security (Instr. 3) 	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8) 	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 	7. Nature of Indirect Beneficial Ownership (Instr. 4) 	
			Code	V	Amount	(A) or (D)	Price				
Common Stock	10/14/2009		P(1) 		13,439,257	A	$1.5 	64,933,295	I	See Footnote(2) 	
Common Stock	10/15/2009		P(3) 		2,015,888	A	$1.5 	66,949,183	I	See Footnote(2) 	
Common Stock								3,891,108	I	See Footnote(4) 	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities) 	
1. Title of Derivative Security (Instr. 3) 	2. Conversion or Exercise Price of Derivative Security 	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) 	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 	8. Price of Derivative Security (Instr. 5) 	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 	11. Nature of Indirect Beneficial Ownership (Instr. 4) 	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
1. Name and Address of Reporting Person*
Ulys, LLC	

(Last)	(First)	(Middle)	
750 LEXINGTON AVENUE	
30TH FLOOR	

(Street) 
NEW YORK	NY	10022	

(City)	(State)	(Zip)	
	
1. Name and Address of Reporting Person*
Invus, L.P.	

(Last)	(First)	(Middle)	
750 LEXINGTON AVENUE	
30TH FLOOR	

(Street) 
NEW YORK	NY	10022	

(City)	(State)	(Zip)	
	
1. Name and Address of Reporting Person*
Invus Advisors, L.L.C.	

(Last)	(First)	(Middle)	
750 LEXINGTON AVENUE	
30TH FLOOR	

(Street) 
NEW YORK	NY	10022	

(City)	(State)	(Zip)	
	
1. Name and Address of Reporting Person*
DEBBANE RAYMOND	

(Last)	(First)	(Middle)	
C/O ULYS, L.L.C., 750 LEXINGTON AVENUE	
30TH FLOOR	

(Street) 
NEW YORK	NY	10022	

(City)	(State)	(Zip)	
	
Explanation of Responses:	
1. On October 8, 2009, Invus, L.P. agreed to purchase 13,439,257 shares of common stock of Lexicon Pharmaceuticals, Inc. (the "Issuer") from the Issuer. The purchase closed on October 14, 2009.	
2. The reported shares are owned directly by Invus, L.P. Invus Advisors, L.L.C. is the general partner of Invus, L.P. Ulys, L.L.C. is the managing member of Invus Advisors, L.L.C. Raymond Debbane is the sole member of Ulys, L.L.C. Accordingly, each of Invus Advisors, L.L.C, Ulys, L.L.C. and Raymond Debbane may be deemed to be indirect beneficial owners of the reported securities. Each of Invus Advisors, L.L.C., Ulys, L.L.C and Raymond Debbane disclaims beneficial ownership of such securities, except to the extent of its or his pecuniary interest therein.	
3. On October 14, 2009, Invus, L.P. agreed to purchase 2,015,888 shares of common stock of Lexicon Pharmaceuticals, Inc. (the "Issuer") from the Issuer. The purchase closed on October 15, 2009.	
4. The reported shares are owned directly by Invus Public Equities, L.P. Invus Public Equities Advisors, L.L.C. is the general partner of Invus Public Equities, L.P. Ulys, L.L.C. is the managing member of Invus Public Equities, L.L.C. Raymond Debbane is the sole member of Ulys, L.L.C. Accordingly, each of Invus Public Equities Advisors, L.L.C, Ulys, L.L.C. and Raymond Debbane may be deemed to be indirect beneficial owners of the reported shares. Each of Invus Public Equities Advisors, L.L.C, Ulys, L.L.C. and Raymond Debbane disclaims beneficial ownership of such shares, except to the extent of its or his pecuniary interest therein.	
	/s/ Raymond Debbane, President : ULYS, L.L.C.	10/15/2009	
	/s/ Raymond Debbane, President : INVUS, L.P., By : Invus Advisors, L.L.C., its general partner	10/15/2009	
	/s/ Raymond Debbane, President : INVUS ADVISORS, L.L.C.	10/15/2009	
	/s/ Raymond Debbane	10/15/2009	
	** Signature of Reporting Person	Date	
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.	
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).	
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).	
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.	
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.